EICHOR
● Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Aggressive Diffuse Large B-cell Lymphoma · High-grade B-cell Lymphoma (HGBL) · Follicular Lymphoma (FL) Grade 3B · Sponsor: Universität Münster
About this study
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
This description comes directly from the study's public registry record.
Talk to the study team
Georg Lenz, Prof. · +492518347587 · lenzsekr@ukmuenster.de
Always discuss trial participation with your own doctor first.
Locations (34)
| Universitaetsklinikum Aachen | Aachen, Germany | Recruiting |
| Universitaetsklinikum Augsburg | Augsburg, Germany | Recruiting |
| Vivantes Netzwerk fuer Gesundheit | Berlin, Germany | Recruiting |
| Charite Universitaetsmedizin Berlin | Berlin, Germany | Recruiting |
| HELIOS Klinikum Berlin-Buch | Berlin, Germany | Recruiting |
| Evangelisches Klinikum Bethel | Bielefeld, Germany | Recruiting |
| Klinikum Chemnitz | Chemnitz, Germany | Recruiting |
| Universitaetsklinikum Duesseldorf | Düsseldorf, Germany | Recruiting |
| Universitaetsklinikum Erlangen | Erlangen, Germany | Recruiting |
| Universitaetsklinikum Essen | Essen, Germany | Not Yet Recruiting |
| Universitaetsklinikum Frankfurt | Frankfurt, Germany | Recruiting |
| Medical Center - University Of Freiburg | Freiburg im Breisgau, Germany | Recruiting |
+ 22 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07197307